产品名称：Tozorakimab
中文名称：托雷奇单抗
产品别称：MEDI-3506
靶点：IL33[Homo sapiens]
抗体亚型：IgG1 - lambda2
来源：CHO-K1 cells
体内研究：在小鼠肺上皮损伤模型中，Tozorakimab能有效抑制炎症反应[1]。
| Animal Model | humanized IL-33 genetically modified mice (lung epithelial injury) |
Dosage | 0.1, 1.0, 3.0 and 10.0 mg/kg |
| Result | dose-dependently inhibited IL-5 levels |
参考文献：1.England E, Rees DG, Scott IC, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023;13(1):9825. Published 2023 Jun 17. doi:10.1038/s41598-023-36642-y
仅供科研使用
